Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 725,782
  • Shares Outstanding, K 54,776
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -169 M
  • EBITDA $ -157 M
  • 60-Month Beta 0.10
  • Price/Sales 25.55
  • Price/Cash Flow N/A
  • Price/Book 20.56

Options Overview Details

View History
  • Implied Volatility 104.14% ( -3.67%)
  • Historical Volatility 165.22%
  • IV Percentile 73%
  • IV Rank 52.58%
  • IV High 180.71% on 07/03/24
  • IV Low 19.24% on 08/09/24
  • Put/Call Vol Ratio 4.94
  • Today's Volume 2,602
  • Volume Avg (30-Day) 3,455
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 76,253
  • Open Int (30-Day) 56,715

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.89
  • Number of Estimates 5
  • High Estimate -0.73
  • Low Estimate -1.02
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +23.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.95 +48.04%
on 04/16/25
16.20 -18.21%
on 05/05/25
+3.60 (+37.31%)
since 04/15/25
3-Month
7.76 +70.75%
on 04/09/25
16.20 -18.21%
on 05/05/25
-0.93 (-6.56%)
since 02/14/25
52-Week
3.73 +255.23%
on 07/05/24
19.18 -30.92%
on 01/07/25
+8.19 (+161.86%)
since 05/15/24

Most Recent Stories

More News
UniQure: Q1 Earnings Snapshot

UniQure: Q1 Earnings Snapshot

QURE : 13.25 (+4.74%)
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

QURE : 13.25 (+4.74%)
uniQure to Announce First Quarter 2025 Financial Results

QURE : 13.25 (+4.74%)
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

QURE : 13.25 (+4.74%)
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

QURE : 13.25 (+4.74%)
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

QURE : 13.25 (+4.74%)
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

QURE : 13.25 (+4.74%)
uniQure Announces Pricing of its Public Offering

QURE : 13.25 (+4.74%)
uniQure Announces Proposed Public Offering

QURE : 13.25 (+4.74%)
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's...

QURE : 13.25 (+4.74%)

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 14.34
2nd Resistance Point 13.81
1st Resistance Point 13.53
Last Price 13.25
1st Support Level 12.72
2nd Support Level 12.19
3rd Support Level 11.91

See More

52-Week High 19.18
Fibonacci 61.8% 13.28
Last Price 13.25
Fibonacci 50% 11.45
Fibonacci 38.2% 9.63
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar